Gilead Remdesivir Price Triggers Analyst Debate on Recouping Investment

In this article Gilead Sciences Inc.’s move to charge less than expected for its coronavirus-fighting drug drew a debate on Wall Street, as analysts sparred over the company’s ability to recoup its more than $1-billion investment in developing and making the medicine. The drug developer announced that commercial patients would pay roughly $3,120 for a […]

AstraZeneca Ponders a Huge $240 Billion Gilead Gamble

There are good reasons for Britain’s AstraZeneca Plc to consider what would be the biggest pharmaceuticals deal in history by combining with U.S. peer Gilead Sciences Inc. They may not be good enough to offset the risks that go with mashing together drugmakers with a total market value of nearly $240 billion. AstraZeneca approached Gilead last […]